Skip to main content
. 2021 Sep 8;13(9):1427. doi: 10.3390/pharmaceutics13091427

Figure 3.

Figure 3

Structures of prominent candidates for a (a) type I ½ and a (b) type II anaplastic lymphoma kinase inhibitor as presented in [7].